Yu Zepeng, Sun Xingwei, Bai Xuming, Ding Wei, Wang WeiDong, Xu Liang, Qin Wenming, Wen Ling, Jin Yong
Department of Intervention, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, Jiangsu, People's Republic of China.
Department of Intervention, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, 214023, Jiangsu Province, People's Republic of China.
Ther Clin Risk Manag. 2021 Feb 4;17:137-144. doi: 10.2147/TCRM.S292230. eCollection 2021.
The totally implantable venous access port (TIVAP) provides patients with safe, effective and long-term convenient venous access for the administration of medications such as chemotherapy drugs. The implantation and long-term use of TIVAP are related to thrombosis, infection and other complications. In this study, the medical records of multicentre patients were collected, and the perioperative and postoperative complications were retrospectively analysed to objectively evaluate the safety of the implantation of supraclavicular, ultrasound-guided TIVAP via the brachiocephalic vein (BCV).
We retrospectively analysed the clinical data of 433 adult patients who had undergone ultrasound-guided TIVAP implantation via the BCV at four hospitals in China from March 2018 to May 2019. The success rates of the first puncture, operation time, and perioperative and postoperative complications were analysed.
All the TIVAPs were implanted successfully (100%). The average TIVAP carrying time was 318.15 ±44.22 days (range: 38-502 days) for a total of 197,694 catheter days. The success rate of the first puncture was 94.92% (411/433), and the average operation time was 29.66 ±7.45 min (range: 18-60 min). The perioperative complications included arterial puncture in 4 patients and pneumothorax in 1 patient. The incidence of postoperative complications was 5.08% (22/433), including poor incision healing (n = 2), catheter-related infection (n = 3), port infection (n = 6), thrombosis (n = 2) and fibrin sheath formation (n = 8). Another patient had infusion disturbance 2 days after the operation, and chest X-ray showed bending at the connection between the catheter and port. No other serious complications occurred, such as catheter rupture and drug leakage. The total incidence of complications was 6.24% (27/433).
This study showed excellent tolerance of supraclavicular, ultrasound-guided BCV puncture to implant TIVAP and a low incidence of complications. As a safe and effective method of TIVAP implantation, it can provide a new choice for clinicians.
全植入式静脉输液港(TIVAP)为患者提供了安全、有效且长期便捷的静脉通路,用于输注化疗药物等。TIVAP的植入及长期使用与血栓形成、感染等并发症相关。本研究收集多中心患者的病历,回顾性分析围手术期及术后并发症,以客观评估经头臂静脉(BCV)行锁骨上超声引导下植入TIVAP的安全性。
我们回顾性分析了2018年3月至2019年5月在中国四家医院接受经BCV超声引导下植入TIVAP的433例成年患者的临床资料。分析首次穿刺成功率、手术时间以及围手术期和术后并发症。
所有TIVAP均成功植入(100%)。TIVAP平均留置时间为318.15±44.22天(范围:38 - 502天),累计导管留置天数为197,694天。首次穿刺成功率为94.92%(411/433),平均手术时间为29.66±7.45分钟(范围:18 - 60分钟)。围手术期并发症包括4例动脉穿刺和1例气胸。术后并发症发生率为5.08%(22/433),包括切口愈合不良(n = 2)、导管相关感染(n = 3)、输液港感染(n = 6)、血栓形成(n = 2)和纤维蛋白鞘形成(n = 8)。另1例患者术后2天出现输液障碍,胸部X线显示导管与输液港连接处弯曲。未发生其他严重并发症,如导管破裂和药物渗漏。并发症总发生率为6.24%(27/433)。
本研究表明锁骨上超声引导下经BCV穿刺植入TIVAP耐受性良好,并发症发生率低。作为一种安全有效的TIVAP植入方法,可为临床医生提供新选择。